suramin has been researched along with Autism in 4 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)." | 5.56 | Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020) |
| "Are the symptoms of autism caused by a treatable metabolic syndrome that traces to the abnormal persistence of a normal, alternative functional state of mitochondria? A small clinical trial published in 2017 suggests this is possible." | 2.58 | Antipurinergic therapy for autism-An in-depth review. ( Naviaux, RK, 2018) |
| "Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)." | 1.56 | Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirsch, MM | 1 |
| Deckmann, I | 1 |
| Santos-Terra, J | 1 |
| Staevie, GZ | 1 |
| Fontes-Dutra, M | 1 |
| Carello-Collar, G | 1 |
| Körbes-Rockenbach, M | 1 |
| Brum Schwingel, G | 1 |
| Bauer-Negrini, G | 1 |
| Rabelo, B | 1 |
| Gonçalves, MCB | 1 |
| Corrêa-Velloso, J | 1 |
| Naaldijk, Y | 1 |
| Castillo, ARG | 1 |
| Schneider, T | 1 |
| Bambini-Junior, V | 1 |
| Ulrich, H | 1 |
| Gottfried, C | 1 |
| Naviaux, RK | 2 |
| Zolkipli, Z | 1 |
| Wang, L | 1 |
| Nakayama, T | 1 |
| Naviaux, JC | 1 |
| Le, TP | 1 |
| Schuchbauer, MA | 1 |
| Rogac, M | 1 |
| Tang, Q | 1 |
| Dugan, LL | 1 |
| Powell, SB | 1 |
| Theoharides, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The UCSD Suramin Autism Treatment-1 (SAT1) Trial[NCT02508259] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The full ABC is a 58-item parent rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. Stereotypy is reported, and scores range from 0 to 21, with higher scores indicating worse behavior. A negative difference corresponds to decreased symptoms after treatment. A positive difference corresponds to increased symptoms after treatment. (NCT02508259)
Timeframe: 6 weeks compared to baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -4.0 |
| Saline (Placebo) | 1.0 |
ADOS2 comparison scores are units on a scale of 0-10. A score of 7-10 was required for enrollment. A score of 7-10 is diagnostic for autism spectrum disorder (ASD). The higher the score, the more severe the core symptoms of autism spectrum disorder. Scores of 6 and below are considered off the ASD spectrum. (NCT02508259)
Timeframe: 6 weeks compared to baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -1.6 |
| Saline (Placebo) | -0.4 |
The reported value is the Language sub-score of the ATEC, and the range for the language sub-score is 0-20. The higher the score, the worse the disability. Outcomes were measured at 6 weeks after treatment compared to baseline. A negative difference corresponds to a decrease in language disability, i.e an improvement in speech and language. A positive difference reflects an increase in language disability, i.e. a decrease in speech and language. (NCT02508259)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -2.0 |
| Saline (Placebo) | -0.2 |
Expressive One Word Picture Vocabulary Test (EOWPVT) scores are normalized for age. Typical language development produces a mean score of 100 with a standard deviation of 15. Outcomes for EOWPVT were expressed as the mean of the child-specific difference before and 6-weeks after treatment. For example, if the 6-week standard EOWPVT score was 59.6 and the baseline score was 63.8, the difference is -4.2 (= 59.6 - 63.8). A decrease in score at 6 weeks would corresponds to a decrease in language performance, while an increase, a positive difference, would reflect an increase. (NCT02508259)
Timeframe: 6 weeks compared to baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -4.2 |
| Saline (Placebo) | 2.0 |
Total repetitive behavior was assessed using the Repetitive behavior questionnaire (RBQ), which has a scale from 0-87. Higher scores correspond to more severe repetitive behavior. Outcomes were analyzed as the difference in the score 6 weeks after treatment compared to baseline. A negative difference corresponds to improved behavior compared to baseline. A positive difference corresponds to worse behavior. (NCT02508259)
Timeframe: 6 weeks compared to baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -3.2 |
| Saline (Placebo) | -0.8 |
The CGI-I is scale that ranges from 1-7, reflecting the change in core autism behaviors after treatment. 1 is much improved, 4 is unchanged, and 7 is much worse. (NCT02508259)
Timeframe: Overall ASD symptoms at 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Suramin | -1.8 |
| Saline (Placebo) | 0.0 |
1 review available for suramin and Autism
| Article | Year |
|---|---|
Antipurinergic therapy for autism-An in-depth review.
Topics: Administration, Intravenous; Adolescent; Autistic Disorder; Child; Child, Preschool; Clinical Trials | 2018 |
3 other studies available for suramin and Autism
| Article | Year |
|---|---|
Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Disease Models, Animal; Female; Locomotion; Male | 2020 |
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model.
Topics: Animals; Autistic Disorder; Behavior, Animal; Brain; Calcium-Calmodulin-Dependent Protein Kinase Typ | 2013 |
Extracellular mitochondrial ATP, suramin, and autism?
Topics: Animals; Autistic Disorder; Female; Male; Suramin | 2013 |